Encyclopedia of AIDS

Living Edition
| Editors: Thomas J. Hope, Douglas Richman, Mario Stevenson

HIV-1 Transmission Blocking Microbicides

Living reference work entry
DOI: https://doi.org/10.1007/978-1-4614-9610-6_144-1

Definition

Current available methods to prevent HIV infection, including condoms, male circumcision, and behavioral interventions, appear insufficient to control the epidemic. This may in part reflect the limited number of options for at-risk groups. Microbicides offer an important alternative strategy for preventing HIV sexual transmission. An effective microbicide should be a safe, acceptable, and affordable product delivered topically as a gel, capsule, tablet, film, or intravaginal ring at the genital (vaginal, penile) and/or gastrointestinal (colorectal) mucosa to prevent, or at least significantly reduce, sexual transmission of HIV and possibly other sexually transmitted infections.

Introduction

Microbicides were originally conceived as affordable, over-the-counter products, not requiring a prescription, that offered protection against a broad spectrum of sexually transmitted diseases. First-generation candidate products included surfactants to disrupt the viral membrane,...

Keywords

Surfactant Adenine Nucleoside Triphosphate Mannose 
This is a preview of subscription content, log in to check access

References

  1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.PubMedCrossRefPubMedCentralGoogle Scholar
  2. Anton PA, Cranston RD, Kashuba A, Hendrix CW, Bumpus NN, Richardson-Harman N, et al. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses. 2012;28(11):1412–21.PubMedCrossRefPubMedCentralGoogle Scholar
  3. CONRAD. Safety and effectiveness of tenofovir gel in the prevention of Human Immunodeficiency Virus (HIV-1) infection in young women and the effects of tenofovir gel on the incidence of Herpes Simplex Virus (HSV-2) infection. 2011. http://clinicaltrials.gov/ct2/show/NCT01386294.
  4. Herrera C, Shattock RJ. Potential use of protease inhibitors as vaginal and colorectal microbicides. Curr HIV Res. 2012;10(1):42–52.PubMedCrossRefGoogle Scholar
  5. Herrera C, Shattock RJ. Candidate microbicides and their mechanisms of action. Curr Top Microbiol Immunol. 2014;383:1–25.Google Scholar
  6. Hillier SL, Moench T, Shattock R, Black R, Reichelderfer P, Veronese F. In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr. 2005;39(1):1–8.PubMedCrossRefGoogle Scholar
  7. Keele BF. Identifying and characterizing recently transmitted viruses. Curr Opin HIV AIDS. 2010;5(4):327–34.PubMedCrossRefPubMedCentralGoogle Scholar
  8. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature. 2009;458(7241):1034–8.PubMedCrossRefPubMedCentralGoogle Scholar
  9. Mehellou Y, De Clercq E. Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J Med Chem. 2010;53(2):521–38.PubMedCrossRefGoogle Scholar
  10. MTN. MTN statement on decision to discontinue use of tenofovir gel in VOICE, a major HIV prevention study in women. 2011. http://www.mtnstopshiv.org/node/3909.
  11. NIAID. Safety and effectiveness of tenofovir 1 % gel, tenofovir disoproxil fumarate, and emtricitabine/tenofovir disoproxil fumarate tablets in preventing HIV in women. 2011. http://clinicaltrials.gov/ct2/show/NCT00705679.
  12. Ramjee G, Kamali A, McCormack S. The last decade of microbicide clinical trials in Africa: from hypothesis to facts. AIDS. 2010;24:S40–9.PubMedCrossRefGoogle Scholar
  13. Shattock RJ, Rosenberg Z. Microbicides: topical prevention against HIV. Cold Spring Harb Perspect Med. 2012;2(2):a007385.PubMedCrossRefPubMedCentralGoogle Scholar
  14. Shattock RJ, Warren M, McCormack S, Hankins CA. AIDS. Turning the tide against HIV. Science. 2011;333(6038):42–3.PubMedCrossRefGoogle Scholar
  15. Zhao B, Mankowski MK, Snyder BA, Ptak RG, Liwang PJ. Highly potent chimeric inhibitors targeting two steps of HIV cell entry. J Biol Chem. 2011;286(32):28370–81.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Section of Infectious Diseases, Division of MedicineImperial CollegeLondonUK